Category: catabolism
Three antiviral targets in the HCV replication complex deliver pangenotypic 8-12 week cures: (1) NS3/4A serine protease — cleaves the HCV polyprotein into functional non-structural proteins (the -previrs); (2) NS5A protein — multifunctional in RNA replication + virion assembly (the -asvirs); (3) NS5B RNA-dependent RNA polymerase — nucleoside analog target (sofosbuvir, covered in AV-1) or non-nucleoside allosteric site (the -buvirs). Modern combinations (sofosbuvir/velpatasvir = Epclusa; sofosbuvir/ledipasvir = Harvoni; glecaprevir/pibrentasvir = Mavyret; elbasvir/grazoprevir = Zepatier) deliver >95% SVR12 across genotypes 1-6.